The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Neupogen (filgrastim) Market Progress Between 2026 And 2030?

The neupogen (filgrastim) market has experienced substantial growth in recent years. This market is projected to expand from $1.4 million in 2025 to $1.48 million in 2026, advancing at a compound annual growth rate (CAGR) of 5.5%. Historically, this expansion has been driven by factors including increased chemotherapy utilization, the elevated infection risk observed in neutropenic patients, the clinical validation of G-CSF therapy, hospital-centric cancer care models, and a scarcity of early treatment options.

The market size for neupogen (filgrastim) is anticipated to experience robust expansion over the coming years. It is projected to reach $1.81 million by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This growth during the forecast period is attributable to several factors, including the rising incidence of cancer, increased adoption of biosimilars, the expansion of outpatient oncology services, enhanced access to biologic therapies, and a heightened focus on preventing infections. Key trends for the forecast period encompass a greater emphasis on supportive care in oncology, broadening of chemotherapy-induced neutropenia management, a surge in the embrace of biologic growth factors, a transition towards outpatient neutropenia treatment, and the expanding utilization of biosimilar alternatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Primary Drivers Are Shaping The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market is anticipated to expand due to the growing occurrence of diverse illnesses. Illnesses represent dysfunctions or structural irregularities within the body, manifesting distinct symptoms or impacting particular areas, frequently stemming from infections, genetic predispositions, environmental influences, or lifestyle choices. This surge in disease prevalence is fueled by an aging global populace, inactive lifestyles, heightened pollution, inadequate nutritional practices, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) helps manage issues arising from chemotherapy-induced neutropenia by stimulating neutrophil generation, thus bolstering the immune system’s capacity to fight off infections in individuals with compromised immunity. Its role is crucial in lowering hospital admissions, mitigating infection dangers, and ensuring continuous cancer therapy for patients undergoing demanding treatments. For example, data from Allergy UK, a UK-based national charity, revealed in April 2024 that over 21 million people in the UK suffer from allergies, which was identified as the most common chronic health condition in 2022. Forecasts suggest that by 2026, half of Europe’s population will experience at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in the UK, a number expected to grow to nearly 3.5 million by 2025 and 4 million by 2030. Consequently, the rising incidence of diverse illnesses is fueling the expansion of the neupogen (filgrastim) market.

What Are The Key Segment Divisions In The Neupogen (filgrastim) Market Segment Structure?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Trends Are Affecting The Direction Of The Neupogen (filgrastim) Market?

Companies active in the neupogen (filgrastim) market are increasingly prioritizing the development of innovative products as filgrastim biosimilars, aiming to offer a cost-effective and accessible treatment option for chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medicines that closely mirror the original filgrastim (Neupogen) in terms of their safety, efficacy, and structure, primarily utilized to stimulate neutrophil production in patients undergoing chemotherapy to prevent neutropenia. For example, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a total of 55 biosimilars approved in the United States as of June 2024. Its indicated use is to lower the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

Which Organizations Are Engaged In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Get The Full Neupogen (filgrastim) Market Report:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Which Region Holds The Highest Market Share In The Neupogen (filgrastim) Market?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neupogen (filgrastim) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.